1 active not recruiting. 1 Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 1 | Active not recruiting 1 |
Follow SLE: new trials by email Literature Review of SLE trials Research Report on SLE
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| AB-101 in Combination With B-Cell Depleting mAb in Patients Who Failed Treatment for Class III or IV Lupus Nephritis or Other Forms of Refractory Systemic Lupus Erythematosus AB-101, Cyclophosphamide, Fludarabine - Lupus Nephritis - WHO Class III, Lupus Nephritis - WHO Class IV | Phase 1 | Active not recruiting | Artiva Biotherapeutics, Inc. | 51 | 2024-04-03 | 2025-12-10 |
Lupus Erythematosus, Systemic (1) · Lupus Nephritis (1)
Autoimmune Diseases (1) · Connective Tissue Diseases (1) · Female Urogenital Diseases (1) · Female Urogenital Diseases and Pregnancy Complications (1) · Glomerulonephritis (1) · Immune System Diseases (1) · Kidney Diseases (1) · Male Urogenital Diseases (1) · Nephritis (1) · Skin and Connective Tissue Diseases (1) · Urogenital Diseases (1) · Urologic Diseases (1)
Cyclophosphamide (1) · Rituximab (1) · fludarabine (1) · obinutuzumab (1)
Artiva Biotherapeutics, Inc. (1)
United States (1)